5 assets in Peritoneal Carcinoma

Therapeutic assets addressing Peritoneal Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Peritoneal Carcinoma	CanariaBio Inc.	P3	BB (70)
Oregovamab Peritoneal Carcinoma	CanariaBio Inc.	P3	B (56)
Omburtamab Peritoneal Carcinoma	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
nm32-2668 Peritoneal Carcinoma	Numab Therapeutics AG	P1	CC (43)
Sct-001 Car-T Cells Peritoneal Carcinoma	Shanghai Gynecologic Oncology Group	P1	CC (43)